The ADHD Stimulant Shortage: Surviving It, the Alternatives, and the Overdiagnosis Debate

For people with ADHD, the medication shortage stopped being news years ago and became a monthly ritual: call pharmacies, beg for partial fills, switch formulations, repeat. In 2026 the situation is better than its worst but far from fixed, with generic amphetamine products still flickering in and out of stock. Alongside the logistics runs a louder argument, that adult ADHD is being overdiagnosed and the demand surge is part of the problem. Here is an honest tour of both, and of the options when the usual tablet simply cannot be found.

In short

• The shortage is real and ongoing in 2026: generic immediate-release amphetamine remains the hardest to find, and several extended-release methylphenidate products come and go.
• Causes stack: production quotas, manufacturing economics on cheap generics, and a genuine surge in diagnosis and demand.
• Non-stimulant medicines exist and work for many people: atomoxetine is the established first alternative, with others used by specialists.
• The overdiagnosis debate is genuinely contested: rising diagnosis reflects both better recognition, especially in adults and women, and looser assessment in parts of the telehealth boom.
• If your medicine is short, the highest-value moves are flexibility on formulation and an early conversation with your prescriber, not a bigger stockpile.

Why is this still going on?

Because the shortage is not one problem but three: capped production quotas, thin margins that make cheap generics unattractive to manufacture, and demand that grew faster than either could adjust. Stimulants are controlled substances, so total production is quota-limited by regulators; quotas have been raised, but slowly. Meanwhile prescriptions, particularly for adults, climbed steeply through the telehealth era. When one product goes short, demand slams into its neighbours and the shortage ripples across formulations, which is why availability differs street by street and month by month. Official shortage databases, like Health Canada's, track the churn but cannot fix its causes.

What are the real alternatives when stimulants are unavailable?

A non-stimulant is the established plan B, and for a meaningful group of people it is a perfectly good plan A. Atomoxetine is the most evidence-backed non-stimulant for ADHD: it works differently, builds effect over weeks rather than hours, is not a controlled substance, and is never subject to stimulant quotas. That slower onset disappoints people expecting a stimulant's immediacy, but steady full-day coverage without the supply anxiety is exactly what some people need. Specialists also use other options case by case, including bupropion off-label where depression co-exists. None of these are identical replacements, and switching is a prescriber conversation, not a pharmacy improvisation.

Within the stimulant world itself, flexibility helps more than loyalty: a different release form, strength to be combined, or an equivalent molecule is often in stock when your exact product is not, and prescribers handle these substitutions every week now.

Is the overdiagnosis argument fair?

Partly, and pretending otherwise helps nobody. Two things are true at once. Adult ADHD was genuinely under-recognised for decades, especially in women, and much of the diagnostic surge is overdue correction. And parts of the boom, particularly the loosest tele-assessment services of recent years, diagnosed at a pace that credible clinicians criticise, an argument laid out in outlets like AJMC. The uncomfortable middle is that both under- and over-diagnosis coexist, and the shortage punishes the people with the clearest need most. If you suspect ADHD, the practical takeaway is to seek a thorough assessment rather than the fastest one: it protects you clinically and it protects the credibility of the diagnosis.

How do I manage a shortage month without making things worse?

Early, flexible, documented.

• Do not run to zero before acting: start the refill hunt a week early, and tell your prescriber the moment supply looks shaky so alternatives can be planned rather than improvised.
• Be flexible on form, not on oversight: equivalent strengths, different release profiles or the non-stimulant route are prescriber decisions that solve most gaps.
• Never borrow, buy informally, or double up after a missed stretch; restarting after gaps sometimes needs dose adjustment, and informal stimulants are a falsified-medicine magnet.
• Mind the withdrawal-free myth: stopping abruptly is not dangerous the way some drugs are, but function crashes are real, so plan coverage for exams, deadlines and driving-heavy weeks first.

The bottom line

The stimulant shortage is a system failure that individual patients cannot fix, but they can stop it being a monthly crisis: flag problems early, stay flexible across formulations, and take the non-stimulant option seriously rather than treating it as defeat. And the overdiagnosis argument, whatever its merits, says nothing about your individual diagnosis; a careful assessment does. Availability differs by country and by month, so work with your prescriber and pharmacy rather than rumour.

This article is educational and does not replace advice from a doctor or pharmacist who knows your health history.